All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
With a fundraising roadshow in the offing, Affitech A/S bolstered its pipeline by taking back in house a preclinical antivascular endothelial growth factor (VEGF) antibody development program it previously had licensed out to Peregrine Pharmaceuticals Inc. (BioWorld International)